Two Sigma Investments LP Grows Stock Holdings in Indivior PLC (NASDAQ:INDV)

Two Sigma Investments LP raised its position in shares of Indivior PLC (NASDAQ:INDV) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 110,880 shares of the company’s stock after buying an additional 2,237 shares during the period. Two Sigma Investments LP owned about 0.08% of Indivior worth $1,378,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of INDV. Mirae Asset Global Investments Co. Ltd. purchased a new position in Indivior in the fourth quarter valued at $56,000. Lazard Asset Management LLC acquired a new position in Indivior in the 4th quarter valued at about $57,000. Stifel Financial Corp increased its position in Indivior by 24.0% in the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company’s stock valued at $158,000 after acquiring an additional 2,450 shares during the period. Rathbones Group PLC increased its position in Indivior by 11.6% in the 4th quarter. Rathbones Group PLC now owns 14,284 shares of the company’s stock valued at $183,000 after acquiring an additional 1,483 shares during the period. Finally, Gotham Asset Management LLC acquired a new position in Indivior in the 4th quarter valued at about $325,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Piper Sandler lowered their price objective on Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th.

Indivior Trading Up 1.8%

Shares of INDV opened at $12.68 on Wednesday. Indivior PLC has a twelve month low of $7.33 and a twelve month high of $18.50. The stock’s 50 day moving average is $10.61 and its two-hundred day moving average is $10.80. The firm has a market capitalization of $1.75 billion, a PE ratio of -36.23 and a beta of 0.98.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.19. The company had revenue of $266.00 million for the quarter, compared to analyst estimates of $240.13 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, sell-side analysts predict that Indivior PLC will post 1.22 EPS for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.